Targeted Delivery Of Doxorubicin To HER2 Positive Tumor Models [Corrigendum]
Authors Gomari H, Forouzandeh Moghadam M, Soleimani M, Ghavami M, Khodashenas S
Received 19 September 2019
Accepted for publication 19 September 2019
Published 27 September 2019 Volume 2019:14 Pages 7919—7920
Gomari H, Forouzandeh Moghadam M, Soleimani M, Ghavami M, Khodashenas S. Int J Nanomedicine. 2019;14:5679–5690.
The authors of this paper have advised that by their mistake, they omitted an important note from the Acknowledgments section on page 5688.
Read the original article
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]